1-7 of 7
J. Siegel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Leslie Kean, Steven J Siegel, Joseph T Schmalz, Stephanie A Bien, Danielle Scheffey, Catherine Sanders, Harlan Robins, Kristy Applegate, Merav Bar, Saurabh Chhabra, Sung W. Choi, William Clark, Suman r Das, Robert R. Jenq, Richard J. Jones, John Levine, Brent R. Logan, Hemant S. Murthy, Armin Rashidi, Marcie L. Riches, Wael Saber, Karamjeet S. Sandhu, Anthony D. Sung, Karilyn Larkin, Monzr M. Al Malki, Mahasweta Gooptu, Hany Elmariah, Amin Alousi, Lyndsey Runaas, Brian C. Shaffer, Andrew R. Rezvani, Najla El Jurdi, Alison Loren, Mary M. Horowitz, Javier Bolanos-Meade, Shernan G. Holtan, Ami S. Bhatt, Miguel-Angel Perales, Susan DeWolf
Journal: Blood
Blood (2023) 142 (Supplement 1): 475.
https://doi.org/10.1182/blood-2023-188032
Published: 2023
Journal Articles

A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Todd A. Fehniger, MD/PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J. Siegel, MD, David D. Hurd, MD, Kristie A. Blum, MD, Andre Goy, MD, Timothy S. Fenske, MD, Amanda Cashen, MD, Nina D. Wagner-Johnston, MD, Kenneth R. Carson, MD, Nancy L. Bartlett, MD
Journal: Blood
Blood (2012) 120 (21): 1623.
https://doi.org/10.1182/blood.V120.21.1623.1623
Published: 2012
Journal Articles

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J. Siegel, Amanda F. Cashen, Kristie A. Blum, Timothy S. Fenske, David D. Hurd, Andre Goy, Stephanie E. Schneider, Catherine R. Keppel, Nina D. Wagner-Johnston, Kenneth R. Carson, Nancy L. Bartlett
Journal: Blood
Blood (2011) 118 (19): 5119–5125.
https://doi.org/10.1182/blood-2011-07-362475
Published: 2011
Includes: Supplemental data
Journal Articles

A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.

Todd A Fehniger, MD, PhD, Sarah Larson, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, Amanda F Cashen, MD, Kristie A Blum, MD, Timothy S. Fenske, MD, David D Hurd, MD, Andre Goy, MD, John F. DiPersio, MD, PhD, Nancy L Bartlett, MD
Journal: Blood
Blood (2009) 114 (22): 3693.
https://doi.org/10.1182/blood.V114.22.3693.3693
Published: 2009
Journal Articles

A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results

Todd A Fehniger, MD, PhD, Sarah Larson, BA, Kathryn Trinkaus, PhD, Marilyn J Siegel, MD, John F DiPersio, MD, PhD, Amanda F Cashen, MD, David D Hurd, MD, Kristie A Blum, MD, Nancy L Bartlett, MD
Journal: Blood
Blood (2008) 112 (11): 2595.
https://doi.org/10.1182/blood.V112.11.2595.2595
Published: 2008
Journal Articles

Impact on Iron Removal of Dose Reduction for Non-Progressive Serum Creatinine Increases during Treatment with the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670).

N. Gattermann, N. Zoumbos, E. Angelucci, G. Drelichman, J. Siegel, E. Glimm, D. Alberti
Journal: Blood
Blood (2006) 108 (11): 3824.
https://doi.org/10.1182/blood.V108.11.3824.3824
Published: 2006
Journal Articles

Long-Term Safety and Tolerability of the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670) in Patients with Transfusional Iron Overload.

M.D. Cappellini, P. Giardina, J. Porter, T. Coates, M.G. Della Porta, J. Siegel, E. Glimm, J. Ford
Journal: Blood
Blood (2006) 108 (11): 1768.
https://doi.org/10.1182/blood.V108.11.1768.1768
Published: 2006